abx-il8
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2001 (NCT00035828)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-8INHIBITOR
CXCL8 inhibitor
Blocks the binding of IL-8 to IL-8 receptors and inhibits IL-8-dependent neutrophil activation, migration, and degranulation.
- Interleukin-8Immunity, passive
CXCL8 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109616 ↗
Also known as
- abx-il8
- abx-il8
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00035828 | Phase 2 | Dec 1, 2001 | Abgenix |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abgenix | For profit | 1 | 1 | 1 | 2001 |
1 organizations
Page 1 / 1